Garvan’s Australian BioResources (ABR) is a state-of-the-art facility for breeding and holding research mice, for the purpose of studying disease. Mouse Engineering at Garvan/ABR (MEGA) offers an integrated service to generate novel genetically modified (GM) mouse lines quickly and cost-effectively, using CRISPR/Cas9 technology. These mouse colonies are critical in progressing research into urgent health priorities, such as cancer, heart disease, skeletal diseases and autoimmune diseases.
CRISPR/Cas9 technology produces rapid, targeted genetic modifications including single nucleotide mutations, constitutive and conditional gene knockouts or reporter gene insertions.
MEGA’s comprehensive service includes:
- project consultation
- strategy design
- sgRNA and Cas9 mRNA preparation
- embryo transfer
- production of founder mice.
Pups are screened at 2–3 weeks of age for the presence of the genetic modification.
For more information about MEGA, please visit the ABR website.
The Garvan Institute operates under strict ethical guidelines. We only use animals in research programs that are of the highest quality and where no alternatives are available. All such work is carried out under licences issued by the Garvan/St Vincent’s Animal Ethics Committee (AEC). The AEC ensures that the use of animals is justified, taking into consideration the scientific or educational benefits and the potential effects on the welfare of the animals. Read more about our policy on animals in research here.